Article Figures & Data
Figures
- FIGURE 1.
Antitumor activity of Abraxane in established MDA-MB-435 xenografts. (A) 3 doses of Abraxane (intravenous injection, 25 mg/kg/dose on days 0, 2, and 4) led to substantial tumor regression but also regrowth after day 14. (B) Body weight of animals treated with PBS or Abraxane.
- FIGURE 2.
Representative decay-corrected whole-body coronal images of female athymic nude mice bearing orthotopic MDA-MB-435 tumors at 1 h after intravenous injection of 18F-FDG (7.4 MBq/mouse) on days 0, 3, 7, 14, and 21 after treatment was initiated. Increased uptake of 18F-FDG was observed on days 3 and 7, decreasing to baseline level on days 14 and 21. (A) PBS control. (B) Abraxane treatment.
- FIGURE 3.
Representative decay-corrected whole-body coronal images of female athymic nude mice bearing orthotopic MDA-MB-435 tumors at 1 h after intravenous injection of 18F-FPPRGD2 (3.7 MBq/mouse) on days 0, 3, 7, 14, and 21 after treatment was initiated. Decreased tumor uptake of 18F-FPPRGD2 was observed on days 3 and 7 but was restored to baseline level on days 14 and 21. (A) PBS control. (B) Abraxane treatment.
- FIGURE 4.
Quantitative small-animal PET region-of-interest analysis of tumor uptake for 18F-FDG (A) and 18F-FPPRGD2 (B).
- FIGURE 5.
Ex vivo overlay staining of tumor sections from PBS- and Abraxane-treated MDA-MB-435 tumors on days 3, 7, and 14. Green = Ki67; red = F4/80; blue = DAPI.
- FIGURE 6.
(A) Ex vivo human integrin staining of tumor sections from PBS- and Abraxane-treated MDA-MB-435 tumors on days 3, 7, and 14. (B) Overlay staining of CD31 (red), murine integrin β3 (green), and DAPI (blue) of tumor sections from PBS- and Abraxane-treated MDA-MB-435 tumors on days 3, 7, and 14.
Tables
- TABLE 1
Experimental Design for Longitudinal 18F-FDG and 18F-FPPRGD2 Imaging of Abraxane Treatment Efficacy and Ex Vivo Histopathology
Day Parameter 0 2 3 4 7 14 21 18F-FPPRGD2 #, + + # + # # # Control Abraxane #, + + # + # # # 18F-FDG Control #, + + # + # # # Abraxane #, + + # + # # # Histology − − − − # = small-animal PET; + = PBS or Abraxane treatment; − = tumor tissue sampling.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Molecular Imaging of Post-Src Inhibition Tumor Signatures for Guiding Dasatinib Combination Therapy
- Early Assessment of Tumor Response to Gefitinib Treatment by Noninvasive Optical Imaging of Tumor Vascular Endothelial Growth Factor Expression in Animal Models
- 18F-Alfatide II and 18F-FDG Dual-Tracer Dynamic PET for Parametric, Early Prediction of Tumor Response to Therapy
- Monitoring Tumor Response to Linifanib Therapy with SPECT/CT Using the Integrin {alpha}v{beta}3-Targeted Radiotracer 99mTc-3P-RGD2
- PET of Glucagonlike Peptide Receptor Upregulation After Myocardial Ischemia or Reperfusion Injury